SCHEMBL1994881

SCHEMBL1994881

CC(=O)Oc1c(F)c(F)cc(F)c1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
CA4 P22748 2/20 0.43
CYP4F2 P78329 2/20 0.43
CYP4A11 Q02928 2/20 0.43
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
PREP P48147 3/20 0.41
CELA1 Q9UNI1 2/20 0.41
KDR P35968 1/20 0.41
BACE1 P56817 1/20 0.40
HTT P42858 3/20 0.39
MAPT P10636 3/20 0.39
KDM4E B2RXH2 3/20 0.39
HSD17B10 Q99714 2/20 0.39
TP53 P04637 1/20 0.39
GAA P10253 1/20 0.39
ALDH1A1 P00352 2/20 0.38
TOP1 P11387 1/20 0.38
ABCB11 O95342 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22701893 0.88 CYP4F2 (0.37) CA1CA2CA4CYP4F2CYP4A11
SCHEMBL12342059 0.87 KDM4E (0.42) CYP4F2CYP4A11CES2CES1PREP
SCHEMBL24436821 0.86 PREP (0.41) CA1CA2CA4CYP4F2CYP4A11
SCHEMBL9839630 0.84 KDM4E (0.46) CYP4F2CYP4A11CES2CES1PREP
SCHEMBL27437747 0.84 POLB (0.41) CYP4F2CYP4A11CES2CES1PREP
SCHEMBL18697369 0.83 CA1 (0.44) CA1CA2CA4CYP4F2CYP4A11
SCHEMBL2153565 0.83 CA1 (0.44) CA1CA2CA4CYP4F2CYP4A11
SCHEMBL28510483 0.82 MTNR1A (0.34) CA1CA2CA4CYP4F2CYP4A11
SCHEMBL2003057 0.82 CES2 (0.45) CYP4F2CYP4A11CES2CES1PREP
SCHEMBL29000115 0.82 PREP (0.40) CA2CYP4F2CYP4A11PREPCELA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106089592-B A kind of double blades wind power generating set with vertical shaft and its working method 徐州工程学院 2018-08-03 CN claimed
CN-106089592-A A kind of double blade wind power generating set with vertical shaft and method of work thereof 徐州工程学院 2016-11-09 CN claimed
US-8952083-B2 Fluorocopolymer composition and its production process ASAHI GLASS COMPANY, LIMITED (JP) 2015-02-10 US claimed
WO-2024121632-A1 USE OF ANTI-CD117 ANTIBODY DRUG CONJUGATE (ADC) CRISPR THERAPEUTICS AG (CH) 2024-06-13 WO disclosed
WO-2024062319-A1 POLYMERS WITH DUAL THERAPEUTIC AGENTS Sony Group Corporation (JP) 2024-03-28 WO disclosed
WO-2024044554-A1 VHH ANTIBODY CONJUGATES WITH HETEROARYL CHELATORS Abdera Therapeutics Inc. (US) 2024-02-29 WO disclosed
WO-2024044549-A1 VHH ANTIBODY CONJUGATES Abdera Therapeutics Inc. (US) 2024-02-29 WO disclosed
WO-2024044552-A1 VHH ANTIBODY DOTA CONJUGATES Abdera Therapeutics Inc. (US) 2024-02-29 WO disclosed
EP-3737418-B1 POLYMERS WITH RIGID SPACING GROUPS COMPRISING BIOLOGICALLY ACTIVE COMPOUNDS SONY GROUP CORP (JP) 2024-02-28 EP disclosed
EP-3294811-B1 ULTRA BRIGHT DIMERIC OR POLYMERIC DYES SONY GROUP CORP (JP) 2024-02-28 EP disclosed
EP-3455299-B1 COMPOSITIONS COMPRISING A POLYMERIC DYE AND A CYCLODEXTRIN AND USES THEREOF SONY GROUP CORP (JP) 2024-01-17 EP disclosed
US-20090162290-A1 METHOD FOR THE SYNTHESIS OF PENTA-PENDANT ENANTIOMER-PURE CHELATORS AND PROCESS FOR THERAPEUTICALLY ACTIVE BIOCONJUGATES PREPARATION BY A COVALENT BINDING THEREOF THERAPHARM GMBH 2009-06-25 US disclosed
US-20090162290-A1 METHOD FOR THE SYNTHESIS OF PENTA-PENDANT ENANTIOMER-PURE CHELATORS AND PROCESS FOR THERAPEUTICALLY ACTIVE BIOCONJUGATES PREPARATION BY A COVALENT BINDING THEREOF THERAPHARM GMBH 2009-06-25 US disclosed
WO-2009075778-A2 NONPEPTIDIC INHIBITORS OF CRUZAIN THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-06-18 WO disclosed
WO-2008056897-A1 CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD LG LIFE SCIENCES LTD. (KR) 2008-05-15 WO disclosed
US-20070071673-A1 Trifunctional reagent for conjugation to a biomolecule MITRA MEDICAL TECHNOLOGY AB (SE) 2007-03-29 US disclosed
US-20070071673-A1 Trifunctional reagent for conjugation to a biomolecule MITRA MEDICAL TECHNOLOGY AB (SE) 2007-03-29 US disclosed
WO-2007028639-A1 METHOD FOR THE SYNTHESIS OF PENTAPENDANT ENANTIOMER-PURE CHELATORS AND PROCESS FOR THERAPEUTICALLY ACTIVE BIO-CONJUGATES PREPARATION BY A COVALENT BINDING OF THEREOF THERAPHARM GMBH (CH) 2007-03-15 WO disclosed
WO-2006033551-A1 CASPASE INHIBITORS CONTAINING DICARBONYLAMINO-ISOXAZOLINE LG LIFE SCIENCES LTD. (KR) 2006-03-30 WO disclosed
WO-2005035497-A1 CASPASE INHIBITOR COMPRISING 2-ALKYL-4-OXOBUTANOYL GROUP AND PHARMACEUTICAL COMPOSITION THEREOF LG LIFE SCIENCES LTD. (KR) 2005-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070071673-A1 Trifunctional reagent for conjugation to a biomolecule UACA, TNFSF11, CD40 CA1 2939/4885CA2 3860/4885CA4 2754/4885
US-20090162290-A1 METHOD FOR THE SYNTHESIS OF PENTA-PENDANT ENANTIOMER-PURE CHELATORS AND PROCESS FOR THERAPEUTICALLY ACTIVE BIOCONJUGATES PREPARATION BY A COVALENT BINDING THEREOF C5, C3AR1, SPR CA1 291/4885CA2 1448/4885CA4 872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.